Attached files

file filename
10-K - 10-K - Evofem Biosciences, Inc.evfm-10k_20171231.htm
EX-32.1 - EX-32.1 - Evofem Biosciences, Inc.evfm-ex321_7.htm
EX-31.2 - EX-31.2 - Evofem Biosciences, Inc.evfm-ex312_258.htm
EX-31.1 - EX-31.1 - Evofem Biosciences, Inc.evfm-ex311_8.htm
EX-21.1 - EX-21.1 - Evofem Biosciences, Inc.evfm-ex211_534.htm
EX-10.29 - EX-10.29 - Evofem Biosciences, Inc.evfm-ex1029_533.htm
EX-10.5 - EX-10.5 - Evofem Biosciences, Inc.evfm-ex105_259.htm
EX-4.7 - EX-4.7 - Evofem Biosciences, Inc.evfm-ex47_532.htm
EX-4.1 - EX-4.1 - Evofem Biosciences, Inc.evfm-ex41_285.htm
EX-3.1 - EX-3.1 - Evofem Biosciences, Inc.evfm-ex31_283.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

 

We consent to the incorporation by reference in the following Registration Statements:          

 

 

(1)

Registration Statement (Form S-3 No. 333-208290) and related prospectus of Neothetics, Inc. pertaining to the registration of common stock, preferred stock, debt securities, warrants and units,

 

 

(2)

Registration Statement (Form S-8 No. 333-203059) pertaining to the 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan of Neothetics, Inc., and

 

 

(3)

Registration Statement (Form S-8 No. 333-200409) pertaining to the Amended and Restated 2007 Stock Plan, as amended, 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan;

 

of our report dated February 26, 2018, with respect to the financial statements of Evofem Biosciences, Inc. (formerly Neothetics, Inc.) included in this Annual Report on Form 10-K of Evofem Biosciences, Inc. for the year ended December 31, 2017.

 

 

                                                                                       /s/ Ernst & Young LLP

/s/ Ernst & Young LLP

 

San Diego, California

February 26, 2018